Joan Herman Sells 38,900 Shares of Paysign (NASDAQ:PAYS) Stock

Paysign, Inc. (NASDAQ:PAYS) EVP Joan Herman sold 38,900 shares of the stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $11.74, for a total value of $456,686.00. Following the sale, the executive vice president directly owned 609,421 shares in the company, valued at approximately $7,154,602.54. The trade was a 6.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Paysign Trading Down 0.6%

Paysign stock opened at $12.34 on Friday. The stock has a 50-day moving average price of $11.53 and a 200 day moving average price of $8.04. Paysign, Inc. has a 52 week low of $3.08 and a 52 week high of $14.43. The stock has a market cap of $696.72 million, a PE ratio of 47.46 and a beta of 0.80.

Paysign (NASDAQ:PAYS) last released its earnings results on Wednesday, August 5th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.05. Paysign had a net margin of 15.67% and a return on equity of 30.13%. The company had revenue of $28.25 million for the quarter, compared to analyst estimates of $26.36 million. Paysign has set its FY 2026 guidance at 0.350-0.370 EPS and its Q3 2026 guidance at 0.090-0.100 EPS. On average, equities analysts predict that Paysign, Inc. will post 0.58 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. Wall Street Zen lowered shares of Paysign from a “strong-buy” rating to a “buy” rating in a research report on Sunday, August 16th. DA Davidson boosted their price target on Paysign from $9.00 to $12.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Weiss Ratings raised Paysign from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, July 29th. Lake Street Capital raised their price objective on Paysign from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, Barrington Research set a $15.00 price objective on Paysign in a research report on Tuesday, August 11th. Three research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $14.00.

Institutional Investors Weigh In On Paysign

Several hedge funds have recently modified their holdings of PAYS. BlackRock Inc. acquired a new position in Paysign during the second quarter worth approximately $25,219,000. Punch & Associates Investment Management Inc. purchased a new position in Paysign during the second quarter worth approximately $16,983,000. Renaissance Technologies LLC boosted its holdings in shares of Paysign by 17.4% in the 1st quarter. Renaissance Technologies LLC now owns 1,531,072 shares of the company’s stock valued at $9,033,000 after purchasing an additional 227,300 shares during the last quarter. Thompson Siegel & Walmsley LLC boosted its holdings in shares of Paysign by 14.8% in the 4th quarter. Thompson Siegel & Walmsley LLC now owns 1,457,941 shares of the company’s stock valued at $7,508,000 after purchasing an additional 187,767 shares during the last quarter. Finally, AWM Investment Company Inc. purchased a new stake in shares of Paysign during the 2nd quarter valued at $6,560,000. 25.89% of the stock is owned by institutional investors and hedge funds.

About Paysign

Paysign, Inc is a financial technology company that provides payment and financial services primarily to the healthcare and pharmaceutical industries. Its platform supports prepaid card programs, digital payments and other disbursement solutions designed to help organizations distribute funds to individuals efficiently and securely.

The company’s services include patient assistance programs that help eligible patients receive financial support for prescription medications and other healthcare costs.